CXA-10 is under investigation in clinical trial NCT03422510 (FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.